Liskiewicz, Arkadiusz http://orcid.org/0000-0002-4102-5373
Khalil, Ahmed
Liskiewicz, Daniela
Novikoff, Aaron
Grandl, Gerald
Maity-Kumar, Gandhari
Gutgesell, Robert M.
Bakhti, Mostafa http://orcid.org/0000-0002-2307-1122
Bastidas-Ponce, Aimée
Czarnecki, Oliver http://orcid.org/0000-0002-1767-658X
Makris, Konstantinos
Lickert, Heiko
Feuchtinger, Annette
Tost, Monica
Coupland, Callum http://orcid.org/0000-0001-8921-3616
Ständer, Lisa
Akindehin, Seun
Prakash, Sneha
Abrar, Faiyaz
Castelino, Russell L. http://orcid.org/0009-0008-7446-6299
He, Yantao
Knerr, Patrick J.
Yang, Bin http://orcid.org/0000-0003-1180-6184
Hogendorf, Wouter F. J. http://orcid.org/0000-0003-3231-5325
Zhang, Shiqi
Hofmann, Susanna M. http://orcid.org/0000-0001-7682-5840
Finan, Brian http://orcid.org/0000-0002-6467-0447
DiMarchi, Richard D. http://orcid.org/0000-0003-0220-4085
Tschöp, Matthias H. http://orcid.org/0000-0002-4744-371X
Douros, Jonathan D.
Müller, Timo D. http://orcid.org/0000-0002-0624-9339
Article History
Received: 15 July 2023
Accepted: 13 October 2023
First Online: 9 November 2023
Competing interests
: M.H.T. is a member of the scientific advisory board of ERX Pharmaceuticals. He was a member of the Research Cluster Advisory Panel (ReCAP) of the Novo Nordisk Foundation between 2017 and 2019. He attended a scientific advisory board meeting of the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, in 2016. He received funding for his research projects by Novo Nordisk (2016–2020) and Sanofi-Aventis (2012–2019). He was a consultant for Bionorica SE (2013–2017), Menarini Ricerche (2016), and Bayer Pharma AG Berlin (2016). As former Director of the Helmholtz Diabetes Center and the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018) and since 2018, as CEO of Helmholtz Zentrum München, he has been responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he discussed potential projects with and has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia, worldwide, including but not limited to pharmaceutical corporations such as Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Medigene, Arbormed, BioSyngen and others. In this role, he was/is responsible for commercial technology transfer activities of his institute(s), including diabetes-related patent portfolios of Helmholtz Zentrum München (for example, WO/2016/188932 A2 or WO/2017/194499 A1). M.H.T. confirms that to the best of his knowledge none of the above funding sources was involved in the preparation of this paper. T.D.M. receives research funding from Novo Nordisk and has received speaking fees from Eli Lilly, AstraZeneca and Novo Nordisk. RDDiM is a co-inventor on intellectual property owned by Indiana University and licensed to Novo Nordisk. He was previously employed by Novo Nordisk. Y.H., P.J.K., B.Y., W.F.J.H., B.F. and J.D.D. are current employees of Novo Nordisk. The remaining authors declare no competing interests.